目的 探討丹七軟膠囊聯(lián)合舒馬普坦治療偏頭痛的臨床療效。方法 選取2017年1月-2019年4月于天津醫(yī)科大學(xué)第二醫(yī)院進(jìn)行治療的偏頭痛患者126例，隨機(jī)分為對照組和治療組，每組各63例。對照組口服琥珀酸舒馬普坦片，100 mg/次，1次/d。治療組在對照組的基礎(chǔ)上口服丹七軟膠囊，5粒/次，3次/d，兩組均連續(xù)治療4周。觀察兩組的臨床療效，比較兩組治療前后頭疼發(fā)作情況、血清基質(zhì)金屬蛋白酶-9（MMP-9）的變化情況。結(jié)果 治療組治療總有效率（95.24%）優(yōu)于對照組（82.54%）（P<0.05）。治療后兩組患者頭疼發(fā)作頻次、發(fā)作程度評分均顯著降低，頭疼發(fā)作持續(xù)時間均顯著縮短（P<0.05）；治療后，治療組頭疼發(fā)作情況顯著優(yōu)于對照組（P<0.05）。治療后，兩組患者M(jìn)MP-9均顯著降低（P<0.05）；且治療后治療組MMP-9顯著低于對照組（P<0.05）。結(jié)論 丹七軟膠囊聯(lián)合舒馬普坦治療偏頭痛具有較好的臨床療效，能夠有效改善患者血液流變學(xué)指標(biāo)，減少頭痛發(fā)作，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the effect of Danqi Soft Capsules combined with sumatriptan in treatment of migraine. Methods Patients (126 cases) with migraine who were treated in the Second Hospital of Tianjin Medical University from January 2017 to April 2019 were randomly divided into control group (63 cases) and treatment groups (63 cases). Patients in the control group were po administered with Sumatriptan Succinate Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Danqi Soft Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and changes of the headache onset and serum MMP-9 in two groups before and after treatment were compared. Results The total effective rate of the treatment group (95.24%) was better than that of the control group (82.54%) (P < 0.05). After treatment, the frequency and severity of headache attacks in both groups were significantly reduced, and the duration of headache attacks was significantly shortened (P < 0.05). After treatment, headache incidence in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, MMP-9 was significantly reduced in both groups (P < 0.05). After treatment, MMP-9 in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Danqi Soft Capsules combined with sumatriptan has good clinical efficacy in treatment of migraine, and can effectively improve hemorheology indicators of patients and reduce headache attacks, which has a certain clinical application value.

R971